Restore Vision Inc., a clinical-stage biotechnology company advancing gene therapies for retinal disorders, today announced the interim clinical results from its ongoing Phase 1/2 first-in-human trial ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results